An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 08 Dec 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms GIFT-R
Sponsors AbbVie

Most Recent Events

02 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
24 Aug 2016 Planned initiation date changed from 1 Jul 2016 to 1 Sep 2016.
24 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight